The Uromigos Episode 11: COVID-19 and Immune Checkpoint Inhibitors for the Treatment of Cancer

Dr. Chuck Drake, physician-scientist at Columbia University, and Dr. Doug Johnson, Assistant Professor of Medicine at Valderbilt, discuss possible risk-benefits of immune checkpoint inhibitors during the COVID-19 pandemic. They touch on pre-clinical considerations for immunotherapy, as well as the clinical aspect in the context of physicians providing immunotherapy and patients receiving it amidst the pandemic.